Table 4.
Chromosome aberrations in thymic lymphomasa
| Tumor
|
Genotype
|
Fragments
|
Breaks
|
Exchangesb
|
End-to-endc
|
Short armd
|
Ne
|
Telomeric fusionf
|
|---|---|---|---|---|---|---|---|---|
| 8200 | p53−/− | 1.0 | 0 | 0.3 | 0 | 0.1 | 50 (80) | ND |
| AN1 | p53−/− | 0.1 | 0.1 | 0.4 | 0.1 | 0.2 | 51 (43) | ND |
| 6141 | p53−/− Rad50+/S | 3.5 | 0.2 | 0.5 | 0 | 0.2 | 54 (100) | 0 |
| 5492 | Rad50S/S | 0.4 | 0.1 | 0.2 | 0.1 | 0.1 | 60 (43) | 0.2 |
| 5587 | Rad50S/S | 0.1 | 0.1 | 0.3 | 0 | 0.3 | 60 (38) | 0.1 |
| 6175 | Rad50S/S | 0.6 | 0.3 | 0.4 | 0.1 | 0 | 50 (62) | 0.1 |
| 5390 | p53−/− Rad50S/S | 0.2 | 0 | 0.2 | 0.1 | 3.1g | 54 (100) | 2.1g |
| 6256 | p53−/− Rad50S/S | 0.3 | 0 | 0.2 | 0.2 | 1.1g | 48 (79) | 0.7g |
| 6531 | p53−/− Rad50S/S | 0.2 | 0.1 | 0.1 | 0 | 0.4g | 50 (40) | 0.2g |
a
Determined by phase contrast analysis.
b
Long-arm chromatid fusions.
c
Long-arm chromosome fusions.
d
Short-arm chromosome fusions.
e
Number of metaphase cells examined (% with at least one aberration).
f
Fusions (including exchanges, end-to-end, and short-arm fusions) per metaphase with telomeric DNA retained; determined in a separate experiment in which FISH was performed with a telomeric repeat probe. ND, not done.
g
p < 0.05 when compared to p53−/− tumors using the Wilcoxon rank sum test.